by The plasma protease C1-inhibitor treatment market consists of drugs which are used for treatment of hereditary angioedema (HAE). HAE is a rare genetic disorder characterized by recurrent attacks of edema (swelling) of the skin in different body parts and internal organs like intestinal tract. The plasma protease C1-inhibitor treatment offers unique advantages over other treatment options like on-demand, short-term treatment and rapid relief. Increased awareness about available treatment options and government initiatives for orphan drugs are fueling the demand for plasma protease C1-inhibitor treatment drugs.
The Global plasma protease C1-inhibitor Treatment Market Demand is estimated to be valued at US$ 6257.99 Bn in 2024 and is expected to exhibit a CAGR of 6.7% over the forecast period 2024 to 2030.
Key Takeaways
Key players: Key players operating in the plasma protease C1-inhibitor treatment market are R&D. Koninklijke Philips N.V., Panasonic Corporation, and Procter & Gamble are among the major participants.
Key opportunities: Increasing research activities for development of subcutaneous and long-acting C1-inhibitor therapies present significant growth opportunities. Emerging economies with high disease incidence also offer lucrative opportunities.
Global expansion: Key players are focusing on expansion in developing regions through acquisitions and collaborations to tap the large untreated population. Increasing expenditure on healthcare andrising awareness level will aid market growth globally over the forecast period.
Market drivers: The increasing prevalence of hereditary angioedema globally is the major market driver. Lack of effective alternatives and strong R&D pipeline with novel therapies in late stages are fueling market growth. Growing patient access to diagnosis and treatment due to awareness programs will further augment the demand.
PEST Analysis
Political: The regulations around plasma-derived therapies and recombinant drugs differ across regions and countries. Changes in these guidelines can positively or negatively impact the demand.
Economic: The overall economic growth and rise in disposable incomes influence the spending on specialty healthcare. A decline in economic conditions can affect the adoption.
Social: Growing awareness among patients about the benefits of targeted therapies and increasing preference for personalized treatment are expected to drive the demand.
Technological: Developments in plasma fractionation techniques, recombinant technologies, and drug delivery methods are helping reduce costs and improve outcomes. Advancements in this area are expanding the market potential.
The geographical regions where the plasma protease C1-inhibitor treatment market in terms of value is concentrated currently are North America and Europe. This is attributed to factors such as the high healthcare expenditures, developed healthcare systems, favorable reimbursement framework, and presence of leading market participants in these regions.
The fastest growing regional market for plasma protease C1-inhibitor treatment is expected to be Asia Pacific over the forecast period. This can be credited to the increasing healthcare investments, expanding patient pool affected by hereditary angioedema, and growing awareness about treatment options in major APAC countries like China and India.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
